A prospective multicenter study on cutaneous reactions reported after Sinopharm COVID-19 vaccination.
Ahmed ShawkyEmad M ElrewinyKhaled GharibManar SallamMofreh MansourMahmoud A RagehPublished in: International journal of dermatology (2022)
Because Sinopharm's cutaneous reactions are frequently mild and self-limiting, vaccination should not be discouraged based on these findings. If the first vaccine dose creates a cutaneous reaction, there is no need to skip the second dose.
Keyphrases